Key Takeaways Novo Nordisk will cut 9,000 jobs, saving DKK 8B annually by 2026 to reinvest in R&D and manufacturing.NVO lowered 2025 profit guidance after slower uptake of Wegovy and Ozempic amid rising competition.The restructuring brings DKK 8B in charges, with most costs booked in Q3 2025, partly offset in Q4.In September 2025, Novo Nordisk (NVO) , under the leadership of its new CEO Mike Doustdar, unveiled a major restructuring plan designed to restore momentum in its core businesses and counter mountin ...